Preventive therapy for tuberculosis in HIV-infected persons: Analysis of policy options based on tuberculin status and CD4+ cell count

Archives of Internal Medicine

Volumn 158, Issue 19, 1998, Pages 2112-2121

  Sawert, Holger ^a   Girardi, Enrico ^b   Antonucci, Giorgio ^b   Raviglione, Mario C ^a   Viale, Pierluigi ^c   Ippolito, Giuseppe ^b  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^c Ospedale Civile   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; ISONIAZID; TUBERCULIN;

ADULT; ARTICLE; CLONAL ANERGY; COHORT ANALYSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; HEALTH CARE POLICY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE EXPECTANCY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY ADJUSTED LIFE YEAR; TUBERCULIN TEST; TUBERCULOSIS;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTITUBERCULAR AGENTS; COST-BENEFIT ANALYSIS; HUMANS; ISONIAZID; ITALY; LIFE EXPECTANCY; PATIENT COMPLIANCE; PROSPECTIVE STUDIES; QUALITY-ADJUSTED LIFE YEARS; SURVIVAL ANALYSIS; TUBERCULOSIS;

EID: 0032569642     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.158.19.2112     Document Type: Article

References (59)

1. Raviglione MC, Snider DE, Kochi A. Global epidemiology of tuberculosis: morbidity and mortality of a worldwide epidemic. JAMA. 1995;273:220-226.
2. Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med. 1989;320:545-550.
3. Small PM, Shafer RW, Hopewell PC, et al. Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection. N Engl J Med. 1993;328:1137-1144.
4. Goletti D, Weissman D, Jackson RW, et al. Effect of Mycobacterium tuberculosis on HIV replication: role of immune activation. J Immunol. 1996;157:1271-1278.
5. Perneger TV, Sudre P, Lundgren JD, Hirschel B. Does the onset of tuberculosis in AIDS predict shorter survival? results of a cohort study in 17 European countries over 13 years: AIDS in Europe Study Group. BMJ. 1995;311:1468-1471.
6. Whalen C, Horsburgh CR, Hom D, Lahart C, Simberkoff M, Ellner J. Accelerated course of human immunodeficiency virus infection after tuberculosis. Am J Respir Crit Care Med. 1995;151:129-135.
7. Leroy V, Salmi LR, Dupon M, et al. Progression of human immunodeficiency virus infection in patients with tuberculosis disease: a cohort study in Bordeaux, France, 1988-1994: the Groupe d'Epidemiologie Clinique du Sida en Aquitaine (GECSA). Am J Epidemiol. 1997;145:293-300.
8. Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis: a general review. Adv Tuberc Res. 1970;17:28-106.
9. Selwyn PA, Sckell BM, Alcabes P, Friedland GH, Klein RS, Schoenbaum EE. High risk of active tuberculosis in HIV-infected drug users with cutaneous anergy. JAMA. 1992;268:504-509.
10. Pape JW, Jean SS, Ho JL, Hafner A, Johnson WD. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet. 1993;342:268-272.
11. Graham NMH, Galai N, Nelson KE, et al. Effect of isoniazid chemoprophylaxis on HIV-related mycobacterial disease. Arch Intern Med. 1996;156:889-894.
12. Hawken MP, Meme HK, Elliott LC, et al. Isoniazid preventive therapy for tuberculosis in HIV-1 - infected adults: results of a randomized controlled trial. AIDS. 1997;11:875-882.
13. Moreno S, Miralles P, Diaz MD, et al. Isoniazid preventive therapy in human immunodeficiency virus - infected persons: long-term effect on development of tuberculosis and survival. Arch Intern Med. 1997;157:1729-1734.
14. Whalen CC, Johnson JL, Okwera A, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. N Engl J Med. 1997;337:801-808.
15. Gordin FM, Matts JP, Miller C, et al. A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. N Engl J Med. 1997;337:315-320.
16. Centers for Disease Control. Purified protein derivative (PPD)-tuberculin anergy and HIV infection: guidelines for anergy testing and management of anergic persons at risk of tuberculosis. MMWR Morb Mortal Wkly Rep. 1991;40(RR-5):27-32.
17. Subcommittee of the Joint Tuberculosis Committee of the British Thoracic Society. Guidelines on the management of tuberculosis and HIV infection in the United Kingdom. BMJ. 1992;304:1231-1233.
18. Chin DP, Osmond D, Page-Shafer K, et al. Reliability of anergy skin testing in persons with HIV infection. Am J Respir Crit Care Med. 1996;153:1982-1984.
19. Centers for Disease Control and Prevention. Anergy skin testing and preventive therapy for HIV-infected persons: revised recommendations. MMWR Morb Mortal Wkly Rep. 1997;46(RR-15):1-10.
20. Masobe P, Lee T, Price M. Isoniazid prophylactic therapy for tuberculosis in HIV-seropositive patients: a least-cost analysis. S Afr Med J. 1995;85:75-81.
21. Heymann SJ. Modelling the efficacy of prophylactic and curative therapies for preventing the spread of tuberculosis in Africa. Trans R Soc Trop Med Hyg. 1993; 87:406-411.
22. Antonucci G, Girardi E, Raviglione MC, Ippolito G. Risk factors for tuberculosis in HIV-infected persons: a prospective cohort study. JAMA. 1995;274:143-148.
23. Salpeter SR. Fatal isoniazid-induced hepatitis: its risk during chemoprophylaxis. West J Med. 1993;159:560-564.
24. Israel HL, Gottlieb JE, Maddrey WC. Perspective: preventive isoniazid therapy and the liver. Chest. 1992;101:1298-1301.
25. Snider DE Jr, Caras GJ. Isoniazid-associated hepatitis deaths: a review of available information. Am Rev Respir Dis. 1992;145:494-497.
26. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Organ. 1982;60:555-564.
27. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13:322-338.
28. McKay MD, Conover WJ, Beckman RJ. A comparison of three methods for selecting values of input variables in the analysis of output from a computer code. Technometrics. 1979;21:239-245.
29. Siegel JE Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses: Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996;276:1339-1341.
30. Holtgrave DR, Pinkerton SD. Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16:54-62.
31. Migliori GB, Spanevello A, Gambarini C, Rieder HL, Neri M. Economical aspects of tuberculosis control in Italy. Rass Pat App Resp. 1994;9:67-70.
32. Ministero della Sanità. Revisione del nomenclatore tariffario delle prestazioni specialistiche ambulatoriali. Gazzetta Ufficiale Repubblica Ital N. 1991;286(suppl 80): 1-78.
33. Snider DE Jr, Caras GJ, Koplan JP. Preventive therapy with isoniazid: cost-effectiveness of different durations of therapy. JAMA. 1986;255:1579-1583.
34. Styblo K. Epidemiology of Tuberculosis. The Hague, the Netherlands: Tuberculosis Association; 1991:40-54.
35. Scalia-Tomba G. Stima dell' epidemia di HIV ed AIDS in Italia basata sui dati di notifica AIDS noti al COA in primavera 1994: rapporti ISTISAN 95/41. In: Pezzotti P, Scalia-Tomba G, Rezza G, eds. Incidenza e Prevalenza delle Infezioni da HIV in Italia e Previsioni a Breve e Medio Termine. Roma, Italia: Istituto Superiore di Sanita; 1995:64-69.
36. Sutherland I. Recent studies in the epidemiology of tuberculosis, based on the risk of being infected with tubercle bacilli. Adv Tuberc Res. 1976;19:1-63.
37. Markowitz N, Hansen NI, Hopewell PC, et al. Incidence of tuberculosis in the United States among HIV-infected persons. Ann Intern Med. 1997;126:123-132.
38. Girardi E, Antonucci G, Tronci M, Bordi E, Ippolito G. Drug resistance patterns among tuberculosis patients in Rome, 1990-1992. Scand J Infect Dis. 1996;28: 487-491.
39. Angarano G, Carbonara D, Costa D. Drug resistance of Mycobacterium tuberculosis strains isolated from HIV-infected Italian patients: preliminary report from a multicentric study. New Microbiol. 1995;18:69-72.
40. Burman WJ, Dalton CB, Cohn DL, Butler JR, Reves RR. A cost-effectiveness analysis of directly observed therapy vs self-administered therapy for treatment of tuberculosis. Chest. 1997;112:63-70.
41. Blatt SP, McCarthy WF, Bucko Krasnicka B, et al. Multivariate models for predicting progression to AIDS and survival in human immunodeficiency virus-infected persons. J Infect Dis. 1995;171:837-844.
42. Longini IM Jr, Clark WS, Byers RH, et al. Statistical analysis of the stages of HIV infection using a Markov model. Stat Med. 1989;8:831-843.
43. Lu Y, Stitt FW. Using Markov processes to describe the prognosis of HIV-1 infection. Med Decis Making. 1994;14:266-272.
44. Mariotto AB, Mariotti S, Pezzotti P, Rezza G, Verdecchia A. Estimation of the acquired immunodeficiency syndrome incubation period in intravenous drug users: a comparison with male homosexuals. Am J Epidemiol. 1992;135:428-437.
45. Schechter MT, Le N, Craib KJ, Le TN, O'Shaughnessy MV, Montaner JS. Use of the Markov model to estimate the waiting times in a moditied WHO staging system for HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;8: 474-479.
46. Jordan TJ, Lewit EM, Montgomery RL, Reichman LB. Isoniazid as preventive therapy in HIV-infected intravenous drug abusers: a decision analysis. JAMA. 1991;265:2987-2991.
47. Fischl ME, Dickinson GM, LaVoie L. Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS. JAMA. 1988;259:1185-1189.
48. 3: a cost-effectiveness analysis. J Acquir Immune Defic Syndr Hum Retrovirol. 1991;4:521-531.
49. Graham NMH, Nelson KE, Solomon L, et al. Prevalence of tuberculin positivity and skin test anergy in HIV-1 - seropositive and - seronegative intravenous drug users. JAMA. 1992;267:369-373.
50. Pan American Health Organization. Association Between HIV and Tuberculosis: Technical Guide. Washington, DC: Pan American Health Organization; 1992.
51. De Cock KM, Grant A, Porter JD. Preventive therapy for tuberculosis in HIV-infected persons: international recommendations, research, and practice. Lancer. 1995;345:833-836.
52. Nazar Stewart V, Nolan CM. Results of a directly observed intermittent isoniazid preventive therapy program in a shelter for homeless men. Am Rev Respir Dis. 1992;146:57-60.
53. Pilote L, Tulsky JP, Zolopa AR, Hahn JA, Schecter GF, Moss AR. Tuberculosis prophylaxis in the homeless: a trial to improve adherence to referral. Arch Intern Wed. 1996;156:161-165.
54. McCarthy BD, Wong JB, Munoz A, Sonnenberg FA. Who should be screened for HIV infection? a cost-effectiveness analysis. Arch Intern Med. 1993;153:1107-1116.
55. Lipsky JJ. Antiretroviral drugs for AIDS. Lancet. 1996;345:833-836.
56. Brodt HR, Kamps BS, Gute P, Knupp B, Staszewski S, Helm E. Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy. AIDS. 1997;11:1731-1738.
57. Brown RE, Miller B, Taylor WR, et al. Health-care expenditures for tuberculosis in the United States. Arch Intern Med. 1995;155:1595-1600.
58. Salpeter SR, Sanders GD, Salpeter EE, Owens DK. Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: a risk-benefit and cost-effectiveness analysis. Ann Intern Med. 1997;127:1051-1061.
59. Brewer TF, Heymann SJ, Colditz GA. Evaluation of tuberculosis control policies using computer simulation. JAMA. 1996;276:1898-1903.